Obexelimab Phase 3 Trial Meets All Endpoints, Published in NEJM
Summary
Zenas BioPharma's Phase 3 Indigo trial for obexelimab successfully met its primary and all key secondary endpoints. This detailed positive outcome, which follows an initial report in a March 8-K filing, was simultaneously presented at the EULAR 2026 Congress and published in the prestigious New England Journal of Medicine. The publication and presentation provide significant external validation for the drug, substantially de-risking its path towards regulatory approval and potential commercial launch.
At the time of this announcement, ZBIO was trading at $17.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $8.91 to $44.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.